Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00569
|
|||||
| Drug Name |
Glycocholic acid
|
|||||
| Synonyms |
Glycocholate; cholylglycine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bile acid synthesis defect [ICD11: 5C52.11] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H43NO6
|
|||||
| Canonical SMILES |
CC(CCC(=O)NCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
|
|||||
| InChI |
InChI=1S/C26H43NO6/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33)/t14-,15+,16-,17-,18+,19+,20-,21+,24+,25+,26-/m1/s1
|
|||||
| InChIKey |
RFDAIACWWDREDC-FRVQLJSFSA-N
|
|||||
| CAS Number |
CAS 475-31-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 465.6 | Topological Polar Surface Area | 127 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
2.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321717
, 103578964
, 103914204
, 104322487
, 111677790
, 11466549
, 11467669
, 11486158
, 121363138
, 124799639
, 126677625
, 134973317
, 135859566
, 136380477
, 137006903
, 141721990
, 143839380
, 144212866
, 152104461
, 160854679
, 162180900
, 17422069
, 25631010
, 29204189
, 29228672
, 4266392
, 47515514
, 47810956
, 47810957
, 48035333
, 48334701
, 49698538
, 49747593
, 50070579
, 50071192
, 50111368
, 5027
, 53790906
, 56416996
, 56463222
, 57325988
, 77551091
, 7887780
, 8145498
, 8157310
, 838311
, 841388
, 85787509
, 92125467
, 93167178
|
|||||
| ChEBI ID |
CHEBI:17687
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [4] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [5] | ||
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [6] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [7] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [6] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT01589523) GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis | |||||
| 2 | Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83. | |||||
| 3 | Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003 Jun 27;278(26):23529-37. | |||||
| 4 | Measurement of transport activities of bile acids in human multidrug resistance-associated protein 3 using liquid chromatography-tandem mass spectrometry. Anal Sci. 2010;26(3):317-23. | |||||
| 5 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 6 | Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. | |||||
| 7 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.